Neurodegenerative diseases such as ALS, Alzheimer’s disease, and frontotemporal dementia have been difficult conditions for drug developers to target. Coya Therapeutics is approaching these conditions as diseases of immune system dysfunction to address the neuroinflammation that underlies them We spoke to Adrian Hepner, president and chief medical officer of Coya, about the role a hyper immune response plays in the progress of neurodegenerative diseases, how the company’s experimental regulatory T cell therapy works to halt that, and its pipeline in development.

Addressing Neurodegenerative Disease by Suppressing a Hyper Immune Response

A public-private consortium is seeking to cut the time it takes to discover and advance new cancer therapies to the clinic to one year from the six years it takes on average today. Accelerating Therapeutics for Opportunities in Medicine, or ATOM, brings together scientists from government, academia, and industry with the ambitious goal of harnessing supercomputers to transform cancer drug discovery into a rapid process that can determine molecules that will be safe and effective before advancing them to human clinical trials. We spoke to Michelle Arkin, a member of ATOM and associate professor of pharmaceutical chemistry at the University of California, San Francisco’s school of Pharmacy, about the consortium, the approach its taking, and why it may alter the way therapies for a much broader range of diseases than cancer are developed.

How a Public-Private Consortium Is Revolutionizing Cancer Drug Discovery

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

How a Public-Private Consortium Is Revolutionizing Cancer Drug Discovery

The Bio Report

Related tracks